Genscript Biotech Corporation
1548
Rankning i aktier
#2133
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Aktiekurs
$4.28
Marknadsvärde
$9.61B
Förändring (1 dag)
0.36%
Förändring (1 år)
107.31%
Land
HK
Handel Genscript Biotech Corporation (1548)
Kategori
Healthcare
Rörelsemarginal för Genscript Biotech Corporation (1548)
Rörelsemarginal per October 2026 TTM: 14.88%
Enligt de senaste finansiella rapporterna och aktiekursen för Genscript Biotech Corporation är företagets nuvarande rörelsemarginal (TTM) 14.88%. Vid slutet av 2023 var rörelsemarginalen 3.12%.
Historik för rörelsemarginal för Genscript Biotech Corporation från 2013 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 14.88% | 853.85% |
| 2024 | 1.56% | -50.00% |
| 2023 | 3.12% | -104.46% |
| 2022 | -70.02% | -9.52% |
| 2021 | -77.39% | 47.89% |
| 2020 | -52.33% | 8.91% |
| 2019 | -48.05% | -2,274.21% |
| 2018 | 2.21% | -91.48% |
| 2017 | 25.93% | 19.33% |
| 2016 | 21.73% | 72.87% |
| 2015 | 12.57% | 23.72% |
| 2014 | 10.16% | -28.90% |
| 2013 | 14.29% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 38.59% | -97.41% |
US
|
|
| -149.01% | -110.01% |
US
|
|
| 25.57% | -98.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.06% |
NL
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.